US Patent Issued to Ventus Therapeutics U.S. on April 22 for "Compounds for inhibiting NLRP3 and uses thereof" (Canadian Inventor)

ALEXANDRIA, Va., June 6 -- United States Patent no. 12,281,112, issued on April 22, was assigned to Ventus Therapeutics U.S. Inc. (Waltham, Mass.).

"Compounds for inhibiting NLRP3 and uses thereof" was invented by Stephane Dorich (Pointe-Claire, Canada).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure relates to inhibitors of NLRP3 useful in the treatment of diseases and disorders inhibited by said protein and having the Formula (I):"

The patent was filed on July 3, 2024, under Application No. 18/763,243.

*For further information, including images, charts and tables, please visit: http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.htm...